GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ESSA Pharma Inc (NAS:EPIX) » Definitions » Price-to-Free-Cash-Flow

EPIX (ESSA Pharma) Price-to-Free-Cash-Flow : N/A (As of May. 12, 2025)


View and export this data going back to 2015. Start your Free Trial

What is ESSA Pharma Price-to-Free-Cash-Flow?

As of today (2025-05-12), ESSA Pharma's share price is $1.68. ESSA Pharma's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2024 was $-0.51. Hence, ESSA Pharma's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for ESSA Pharma's Price-to-Free-Cash-Flow or its related term are showing as below:

EPIX's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 29.405
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

ESSA Pharma's Free Cash Flow per Share for the three months ended in Dec. 2024 was $-0.15. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $-0.51.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 8.10% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 17.70% per year. During the past 10 years, the average Free Cash Flow per Share Growth Rate was 29.00% per year.

During the past 11 years, ESSA Pharma's highest 3-Year average Free Cash Flow per Share Growth Rate was 60.10% per year. The lowest was -65.00% per year. And the median was 28.75% per year.


ESSA Pharma Price-to-Free-Cash-Flow Historical Data

The historical data trend for ESSA Pharma's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ESSA Pharma Price-to-Free-Cash-Flow Chart

ESSA Pharma Annual Data
Trend Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

ESSA Pharma Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of ESSA Pharma's Price-to-Free-Cash-Flow

For the Biotechnology subindustry, ESSA Pharma's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ESSA Pharma's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ESSA Pharma's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where ESSA Pharma's Price-to-Free-Cash-Flow falls into.


;
;

ESSA Pharma Price-to-Free-Cash-Flow Calculation

ESSA Pharma's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=1.68/-0.505
=N/A

ESSA Pharma's Share Price of today is $1.68.
ESSA Pharma's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.51.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

ESSA Pharma  (NAS:EPIX) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


ESSA Pharma Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of ESSA Pharma's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


ESSA Pharma Business Description

Traded in Other Exchanges
N/A
Address
999 West Broadway Street, Suite 720, Vancouver, BC, CAN, V5Z 1K5
ESSA Pharma Inc is a pharmaceutical company. The company was focused on the development of small-molecule drugs for the treatment of castration-resistant prostate cancer. It was developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival. Currently, the company has terminated its clinical trials and other studies.
Executives
Biotech Growth N V 10 percent owner ARA HILL TOP BUILDING, UNIT A-5, PLETTERIJWEG OOST 1, CURACAO, WILLEMSTAD P8 000000
Peter Virsik officer: Chief Operating Officer 131 ESCANYO WAY, PORTOLA VALLEY CA 94028
David Ross Parkinson director, officer: Chief Executive Officer C/O THRESHOLD PHARMACEUTICALS, INC., 170 HARBOR WAY SUITE 300, SOUTH SAN FRANCISCO CA 94080
Franklin M Berger director 1000 MARINA BLVD, STE 200, BRISBANE CA 94005
Lauren Merendino director C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005
David S. Wood officer: Chief Financial Officer 3516 WEST 33RD AVE, VANCOUVER A1 V6N 2H4
Philip W. Kantoff director 3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104
Bvf Gp Holdings Llc 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Ii Gp Llc other: See Explanation of Responses 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf I Gp Llc 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Partners Os Ltd. other: See Explanation of Responses P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Mark N Lampert 10 percent owner 1 SANSOME ST, 30TH FL, SAN FRANCISCO CA 94104
Biotechnology Value Fund Ii Lp other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Inc/il 10 percent owner 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Partners L P/il 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104

ESSA Pharma Headlines

From GuruFocus